CORONARY VASODILATORS

Antiarrhythmic effects of coronary vasodilators on canine ventricular arrhythmia models.

Antiarrhythmic effects of intravenous coronary vasodilators (verapamil, diltiazem, bepridil, trimetazidine and nicorandil) were evaluated using two canine ventricular arrhythmia models (halothane-adrenaline arrhythmia and digitalis arrhythmia), and the minimum effective plasma concentrations of the drugs were determined for each arrhythmia model. Verapamil (0.1 mg/kg), diltiazem (0.1 mg/kg), be...

Pulmonary vasodilators.

Pulmonary vasodilators are an important treatment for pulmonary arterial hypertension. They reduce pulmonary artery pressure; improve hemodynamic function; alter ventilation/perfusion matching in the lungs; and improve functional quality of life, exercise tolerance, and survival in patients with severe pulmonary arterial hypertension. This paper reviews the currently available pulmonary vasodil...

Vasodilators in pulmonary hypertension.

Antianginal Agents and Vasodilators

“We now know that the coronary blood vessels in the atherosclerotic heart already are dilated and that ordinary doses of dilator drugs do not significantly increase blood supply to the heart; instead, anginal pain is relieved by a reduction of cardiac consumption of oxygen.” Although vasodilators are used in the treatment of angina, a more sophisticated understanding of the hemodynamic response...

Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation.

Cytochrome P450 epoxygenases convert arachidonic acid into 4 epoxyeicosatrienoic acid (EET) regioisomers, which were recently identified as endothelium-derived hyperpolarizing factors in coronary blood vessels. Both EETs and their dihydroxyeicosatrienoic acid (DHET) metabolites have been shown to relax conduit coronary arteries at micromolar concentrations, whereas the plasma concentrations of ...